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Background
Th e safety and eﬃ  cacy of hydroxyethyl starch (HES) for 
ﬂ uid resuscitation have not been fully evaluated, and 
adverse eﬀ ects of HES on survival and renal function 
have been reported.
Methods
We randomly assigned 7,000 patients who had been 
admitted to an intensive care unit (ICU) in a 1:1 ratio to 
receive either 6% HES with a molecular weight of 
130  kDa and a molar substitution ratio of 0.4 (130/0.4, 
Voluven; Fresenius Kabi AG, Bad Homburg vor der 
Höhe, Germany) i n 0.9% sodium chloride or 0.9% sodium 
chloride (saline) for all ﬂ uid resuscitation until ICU 
discharge, death, or 90  days after randomization. Th e 
primary outcome was death within 90 days. Secondary 
outcomes included acute kidney injury and failure and 
treatment with renal replacement therapy.
Objective: We conducted a large-scale randomized con-
trolled trial to evaluate the safety and eﬃ  cacy of 6% HES 
(130/0.4) in 0.9% saline as compared with 0.9% saline 
alone for ﬂ uid resuscitation in a heterogeneous popu-
lation of adult patients in the ICU.
Design: Th e Crystalloid versus Hydroxyethyl Starch Trial 
(CHEST) was an investigator-initiated, multicenter, 
prospective, blinded, parallel-group, randomized con-
trolled trial.
Setting: Th e study was set at 32 hospitals in Australia and 
New Zealand.
Subjects: Th e subjects were adult patients (>18  years) 
who were admitted to the ICU and who required intra-
venous ﬂ uid above maintenance requirements deter-
mined by the treating clinician and supported by at least 
one objective physiological criterion. Patients were 
excluded if they received more than 1 L of 6% HES within 
24  hours of screening or had one of the following: 
dialysis-dependent or impending dialysis renal failure, 
computed tomography evidence of non-traumatic 
intracranial hemorrhage (ICH) or severe traumatic ICH, 
creatinine of more than 3.9 mg/dL or urine output of less 
than 10  mL/hour for 12  hours, sodium of more than 
160  meq/L, or chloride of more than 130  meq/L. Also 
excluded were females of childbearing age (unless proven 
not to be pregnant) and patients who had post-cardiac 
surgery status, liver transplant, or burns and those whose 
death was judged to be imminent or whose underlying 
disease process indicated a life expectancy of less than 
90 days.
Intervention: If ﬂ uid was deemed necessary by the treat-
ing clinician by the parameters described above, the 
patient received ‘study’ ﬂ uid with identical packaging and 
appearance. Th e ﬂ uid was either 6% HES (130/0.4) in 
saline (Voluven) or 0.9% saline.
Outcomes: Th e primary outcome was death within 
90  days. Secondary outcomes were acute kidney injury 
(AKI) and failure and treatment with renal replacement 
therapy.
Results
A total of 597 (18.0%) of 3,315 patients in the HES group 
and 566 (17.0%) of 3,336 in the saline group died (relative 
risk (RR) in the HES group 1.06, 95% conﬁ dence interval 
(CI) 0.96 to 1.18; P  =  0.26). Th ere was no signiﬁ cant 
diﬀ erence in mortality in six predeﬁ ned subgroups. 
AKI – deﬁ ned by RIFLE (Risk, Injury, Failure, Loss, and 
End-stage kidney disease) criteria  – occurred in few 
patients receiving HES (34.6%) compared with saline 
(38%) (RR 0.91, 95% CI 0.85 to 0.97). However, renal 
replacement therapy was used in 235 (7.0%) of 3,352 
patients in the HES group and 196 (5.8%) of 3,375 in the © 2010 BioMed Central Ltd
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saline group (RR 1.21, 95% CI 1.00 to 1.45; P = 0.04). HES 
was signiﬁ cantly associated with more adverse events 
(5.3% versus 2.8%; P <0.001).
Conclusions
In patients in the ICU, there was no signiﬁ cant diﬀ erence 
in 90-day mortality between patients resuscitated with 
6% HES (130/0.4) or saline. However, despite a lower 
overall rate of AKI, more patients who received resus ci-
tation with HES were given renal replacement therapy. 
(Th e study was supported by the National Health and 
Medical Research Council of Australia; the Ministry of 
Health, New South Wales Government, Australia; and 
Fresenius Kabi; and by a Practitioner Fellowship from the 
National Health and Medical Research Council of 
Australia (to Drs Myburgh and Bellomo), by a Principal 
Research Fellowship from the National Health and 
Medical Research Council of Australia (to Dr Cass), and 
by a Practitioner Fellowship from the Medical Research 
Foundation of the Royal Perth Hospital (to Dr Webb); 
CHEST ClinicalTrials.gov number NCT00935168.)
Commentary
Th e colloid-crystalloid debate has lingered for decades, 
resulting in the overall conclusion that composition of 
ﬂ uids for resuscitation does not inﬂ uence morbidity or 
mortality in the general intensive care unit (ICU) 
population and that the only diﬀ erence involves cost [1]. 
Even with the advent of ‘safer’ hydroxyethyl starches 
(HESs) [2,3], a mortality beneﬁ t remains elusive. How-
ever, human studies [4,5] suggest that ﬂ uid therapies may 
not be as innocuous as once thought and that they may 
cause renal injury and perhaps aﬀ ect mortality in speciﬁ c 
subgroups.
Th e ﬁ rst adequately powered, randomized, blinded 
study drawing attention to these potential diﬀ erential 
eﬀ ects was the Saline versus Albumin Fluid Evaluation 
(SAFE) study. Th is study found no diﬀ erences in mor-
tality in the general ICU population but did ﬁ nd trends 
toward increased survival in patients with sepsis and 
increased mortality in patients with traumatic brain 
injury [6], suggesting that these diﬀ erential eﬀ ects do 
exist and that they may be determined by the population 
studied. More recently, the VISEP (Eﬃ  cacy of Volume 
Substitution and Insulin Th erapy in Severe Sepsis) trial 
[7] addressed the safety and eﬃ  cacy of HES versus 
lactated ringer’s solution in patients with severe sepsis 
and septic shock. Th ese investigators demonstrated that 
HES increases risk of acute kidney injury (AKI) and renal 
replacement therapy. Similarly, a meta-analysis that 
included the VISEP trial showed an increased risk of AKI 
in the general population and an increased risk of AKI 
and use of renal replacement therapy in patients with 
sepsis. However, the VISEP trial used high doses of 
hyperoncotic HES and may not be relevant to usual 
practice. Finally, a meta-analysis by Perel and colleagues 
[8], which included both SAFE and VISEP trials, failed to 
show diﬀ erences in mortality in hospitalized patients but 
recommended that future trials focus on speciﬁ c 
subgroups. Taken together, these data suggested that 
ﬂ uid composition may be important, at least in certain 
subgroups of critically ill patients, especially in patients 
with sepsis. Th e Scandinavian 6S trial attempted to 
answer this question by randomly assigning patients with 
severe sepsis to receive HES in a ringer’s acetate solution 
compared with carrier solution alone. Th e 6S trial found 
a higher risk of 90-day mortality (relative risk  = 1.17, 
P  =  0.03) and greater use of renal replacement therapy 
with HES as compared with those receiving ringer’s 
acetate [9]. However, whether the increased mortality 
and morbidity risk were present in a more heterogeneous 
ICU population was still unknown. Whether other forms 
of HES carry a similar risk is also unclear from the 6S 
trial. Th e Crystalloid versus Hydroxyethyl Starch Trial 
(CHEST) sought to answer these questions.
CHEST was a well-conducted, blinded, randomized 
trial that used a patient-centered outcome such as 90-day 
mortality as the primary aim and that was adequately 
powered to ﬁ nd diﬀ erences between groups using the 
intention-to-treat principle. Th e authors were cautious to 
ensure that the intervention ﬂ uids of the two arms of the 
study had the expected composition by performing inde-
pendent and random biochemical analyses. In addition, 
the study targeted a more general ICU patient population, 
as compared to other recent clinical trials evaluating 
crystalloids versus colloids, such as 6S. Importantly, the 
CHEST was designed to allow for a diﬀ erence in ﬂ uid 
volumes between each arm, whereas 6S proscribed equal 
volumes. Limitations to this study include the following: 
(a)  predeﬁ ned criteria for the initiation of renal 
replacement therapy were absent, (b) the observed death 
rate was lower than the predicted death rate, and this 
may lead to diﬃ  culties in detecting mortality diﬀ erences, 
(c)  the patients who were less sick (than 6S trial) and 
elective surgical patients were included, and (d) the time 
to resolution of the objective parameter (heart rate, blood 
pressure, respiratory varia tion of systolic or mean arterial 
blood pressure, central venous pressure, capillary reﬁ ll, 
and urine output) used to support a diagnosis of 
hypovolemia was not compared between the groups.
Th e CHEST found no diﬀ erence in 90-day mortality 
between patients receiving 6% HES (130/0.4) and those 
receiving 0.9% saline. Interestingly, the use of renal 
replacement therapy was greater in patients receiving 
HES, even though by RIFLE (Risk, Injury, Failure, Loss, 
and End-stage kidney disease) criteria the saline group 
had more AKI. Post hoc analysis suggested that increases 
in creatinine were more pronounced in the HES group, 
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perhaps prompting the small but signiﬁ cant increased 
use of renal replacement therapy. Shaw and Kellum [10] 
(2013) theorize that this paradox may be explained by a 
reduction in glomerular ﬁ ltration rate by HES despite 
better early urine output due to more eﬀ ective volume 
expansion with the colloid. Furthermore, clinicians may 
be trading short-term improvements in hemodynamics 
and urine ﬂ ow for long-term renal toxicity [10]. Whether 
some patients would beneﬁ t from better resuscitation 
eﬃ  ciency (that is, achieving resus ci tation goals faster 
with less ﬂ uid) even at the expense of some renal toxicity 
cannot be addressed by this or the 6S trial. Finally, the 
CHEST enrolled patients an average of 11 hours after 
ICU admission, and most 6S patients were already 
resuscitated prior to study entry. Th us, these aspects of 
the colloid-crystalloid debate rage on. It will be important 
to see the one-year outcome follow-up data yet to be 
published. In the meantime, the existing data conﬁ rm a 
renal toxicity signal from HES not only in patients with 
sepsis but also in the general ICU population.
Recommendations
Given this evidence of renal toxicity and in spite of the 
uncertainty of the eﬀ ect on resuscitation eﬃ  ciency, we 
believe that HES should be avoided in patients with 
severe sepsis as well as in other critically ill patients at 
high risk of AKI. Th ere is no doubt that the colloid-
crystalloid debate has been informed by these two trials. 
However, the remaining uncertainty on aspects such as 
resuscitation eﬃ  ciency and timing of intervention just 
might gather enough rumble for a thirteenth round.
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